Effectiveness, survival and prescription patterns of Janus kinase inhibitors in rheumatoid arthritis: results of a 5.9-year follow-up from the Italian Study Group of Early Arthritis (GISEA) registry.
This large real-world study confirms the effectiveness of JAKis in RA, with valuable insights into factors influencing treatment survival and evolving prescription trends.